




PHARMACEUTICAL 2019

Paratek Pharmaceuticals Inc.
Rank 265 of 363





PHARMACEUTICAL 2019

Paratek Pharmaceuticals Inc.
Rank 265 of 363



The relative strengths and weaknesses of Paratek Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Paratek Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 30% points. The greatest weakness of Paratek Pharmaceuticals Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 206% points.

The company's Economic Capital Ratio, given in the ranking table, is -11%, being 48% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	255,243
Cost of Goods Sold	0
Intangible Assets	829
Liabilities, Current	17,709
Liabilities, Non-Current	234,905
Other Assets	42,947
Other Compr. Net Income	30
Other Expenses	11,523
Other Liabilities	0
Other Net Income	3,216
Other Revenues	17,117
Property and Equipment	1,173
Research and Development	57,508
Selling, General and Administrative Expense	63,658

Output Variable	Value in 1000 USD
Assets	300,192
Liabilities	252,614
Expenses	132,689
Revenues	17,117
Stockholders Equity	47,578
Net Income	-112,356
Comprehensive Net Income	-112,341
Economic Capital Ratio	-11%